Subscribe to Journal
Get full journal access for 1 year
only $33.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Yeung, A. et al. A cost-effectiveness analysis of genomic sequencing in a prospective versus historical cohort of complex pediatric patients. Genet. Med. 22, 1986–1993 (2020).
Li, C. et al. Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies. Genet. Med. https://doi.org/10.1038/s41436-020-01012-w (2020).
Assasi, N., Schwartz, L., Tarride, J. E., Goeree, R. & Xie, F. Economic evaluations conducted for assessment of genetic testing technologies: a systematic review. Genet. Test. Mol. Biomarkers. 16, 1322–1335 (2012).
Schwarze, K., Buchanan, J., Taylor, J. C. & Wordsworth, S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet. Med. 20, 1122–1130 (2018).
Alam, K. & Schofield, D. Economic evaluation of genomic sequencing in the paediatric population: a critical review. Eur. J. Hum. Genet. 26, 1241–1247 (2018).
Coyle, D. et al. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. Eur. J. Health Econ. 21, 1421–1437 (2020).
Willke, R. J., Neumann, P. J., Garrison, L. P. Jr. & Ramsey, S. D. Review of recent US value frameworks-a health economics approach: an ISPOR special task force report . Value Health. 21, 155–160 (2018).
Garrison, L. P. Jr., Pauly, M. V., Willke, R. J. & Neumann, P. J. An overview of value, perspective, and decision context-a health economics approach: an ISPOR special task force report . Value Health. 21, 124–130 (2018).
Husereau, D. et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Pharmacoeconomics. 31, 361–367 (2013).
Arora, V., Moriates, C. & Shah, N. The challenge of understanding health care costs and charges. AMA J. Ethics. 17, 1046–1052 (2015).
Barnett, P. G. An improved set of standards for finding cost for cost-effectiveness analysis. Med. Care. 47 7Suppl 1, S82–S88 (2009).
Jacobs, J. C. & Barnett, P. G. Emergent challenges in determining costs for economic evaluations. Pharmacoeconomics. 35, 129–139 (2017).
Xu, X., Lazar, C. M. & Ruger, J. P. Microcosting in health and medicine: a critical appraisal. Health Econ. Rev. 11, 1 (2021).
Tsiplova, K. et al. A microcosting and cost-consequence analysis of clinical genomic testing strategies in autism spectrum disorder. Genet. Med. 19, 1268–1275 (2017).
van Nimwegen, K. J. et al. Is the $1000 genome as near as we think? A cost analysis of next-generation sequencing. Clin Chem. 62, 1458–1464 (2016).
Jegathisawaran, J., Tsiplova, K., Hayeems, R. & Ungar, W. J. Determining accurate costs for genomic sequencing technologies-a necessary prerequisite. J. Community Genet. 11, 235–238 (2020).
Tan, T. Y. et al. A head-to-head evaluation of the diagnostic efficacy and costs of trio versus singleton exome sequencing analysis. Eur. J. Hum. Genet. 27, 1791–1799 (2019).
Schwarze, K. et al. The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom. Genet. Med. 22, 85–94 (2020).
Sabatini, L. M. et al. Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the Association for Molecular Pathology. J. Mol. Diagn. 18, 319–328 (2016).
Farnaes, L. et al. Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization. NPJ Genom Med. 3, 10 (2018).
Dragojlovic, N. et al. The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study. Genet. Med. 20, 1013–1021 (2018).
Frakt, A. B. & Chernew, M. E. The importance of relative prices in health care spending. JAMA. 319, 441–442 (2018).
Reinhardt, U. E. Priced Out: The Economic and Ethical Costs of American Health Care. (Princeton University Press, Princeton, 2019).
Bai, G. & Anderson, G. F. Extreme markup: the fifty US hospitals with the highest charge-to-cost ratios. Health Aff. (Millwood). 34, 922–928 (2015).
Fishman, P. A. & Hornbrook, M. C. Assigning resources to health care use for health services research: options and consequences. Med. Care. 47 7Suppl 1., S70–S75 (2009).
Kim, D. D. et al. Perspective and costing in cost-effectiveness analysis, 1974-2018. Pharmacoeconomics. 38, 1135–1145 (2020).
Tan, T. Y. et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. JAMA Pediatr. 171, 855–862 (2017).
Basu, A. in Cost-Effectiveness in Health and Medicine. (eds Neumann, P. J. et al.) Estimating costs and valuations of non-health benefits in cost-effectiveness analysis (Oxford University Press, Oxford, 2017).
Biener, A. I. & Selden, T. M. Public and private payments for physician office visits. Health Aff. (Millwood). 36, 2160–2164 (2017).
Allen, H., Gordon, S. H., Lee, D., Bhanja, A. & Sommers, B. D. Comparison of utilization, costs, and quality of Medicaid vs subsidized private health insurance for low-income adults. JAMA Netw. Open. 4, e2032669 (2021).
Sboner, A., Mu, X. J., Greenbaum, D., Auerbach, R. K. & Gerstein, M. B. The real cost of sequencing: higher than you think! Genome Biol. 12, 125 (2011).
Wright, C. F. et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Lancet. 385, 1305–1314 (2015).
Lee, H. et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. 312, 1880–1887 (2014).
Grosse, S. D. & Farnaes, L. Genomic sequencing in acutely ill infants: what will it take to demonstrate clinical value? Genet. Med. 21, 269–271 (2019).
Brunelli, L. et al. Targeted gene panel sequencing for the rapid diagnosis of acutely ill infants. Mol. Genet. Genom. Med. 7, e00796 (2019).
Wang, H. et al. Clinical utility of 24-h rapid trio-exome sequencing for critically ill infants. NPJ Genom. Med. 5, 1–6 (2020).
Schofield, D., Rynehart, L., Shresthra, R., White, S. M. & Stark, Z. Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes. Genet. Med. 21, 2586–2593 (2019).
National Human Genome Research Institute. The cost of sequencing a human genome. https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost (2021).
We thank Louis Garrison, Donald Husereau, and an anonymous reviewer for helpful comments. The findings and conclusions in this paper are those of the authors and do not necessarily represent the official positions of the Centers for Disease Control and Prevention or Intermountain Healthcare.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Grosse, S.D., Gudgeon, J.M. Cost or price of sequencing? Implications for economic evaluations in genomic medicine. Genet Med (2021). https://doi.org/10.1038/s41436-021-01223-9